TOIIW (The Oncology Institute) Stock Based Compensation: $4.78 Mil (TTM As of Mar. 2026)


TOIIW The Oncology Institute Inc TOIIW
56 GF Score
Price $0.06
! 6 Warning Signs
View Full Analysis

What is The Oncology Institute Stock Based Compensation?

The Oncology Institute TOIIW 56 Stock Based Compensation is $4.78 Mil as of Mar. 2026. GuruFocus rates TOIIW with a GF Score™ of 56/100. The stock has 6 warning signs investors should review.

The Oncology Institute's Stock Based Compensation for the three months ended in Mar. 2026 was $1.69 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $4.78 Mil.

The Oncology Institute Stock Based Compensation Related Terms

The Oncology Institute Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for The Oncology Institute's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Oncology Institute Stock Based Compensation Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 24.54 27.68 17.81 11.15 4.55

The Oncology Institute Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.46 0.75 1.02 1.32 1.69
TOIIW
56GF Score
The Oncology Institute Inc TOIIW
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The Oncology Institute Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.78 Mil.

What does a Stock Based Compensation of $4.78 Mil mean?
The Oncology Institute (TOIIW) has a Stock Based Compensation of $4.78 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for The Oncology Institute and its competitors.
Is The Oncology Institute's Stock Based Compensation too high?
The Oncology Institute's current Stock Based Compensation is $4.78 Mil. Overall, The Oncology Institute has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Stock Based Compensation compare to CYH and SRTA?
The Oncology Institute's Stock Based Compensation of $4.78 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Healthcare Providers & Services company?
A good Stock Based Compensation depends on the Healthcare Providers & Services industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for The Oncology Institute and its competitors. The Oncology Institute's current Stock Based Compensation is $4.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current Stock Based Compensation of $4.78 Mil. The current Stock Based Compensation is $4.78 Mil. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current Stock Based Compensation is $4.78 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The Oncology Institute Business Description

Other Exchanges TOI:USA
Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score

Get the complete analysis for TOIIW

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.06
Price